Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Saavedra

Showing results (181-190 of 209) with videos related to

Pageof 21
Sort By:
Journal of Medicinal Chemistry|July 11, 2006
Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivoPaul J Shami, Joseph E Saavedra, Challice L Bonifant, et al.
The Journal of Organic Chemistry|April 28, 2001
The secondary amine/nitric oxide complex ion R(2)N[N(O)NO](-) as nucleophile and leaving group in S9N)Ar reactionsJ E Saavedra, A Srinivasan, C L Bonifant, et al.
Anales De Pediatria (Barcelona, Spain : 2003)|February 6, 2004
[Change in attitude to bicycle helmets after serious accidents]M Fernández Sanmartín, P Cabanas Rodríguez, M Granero Asencio, et al.
The Journal of Organic Chemistry|January 18, 2003
Preparation and reactivity of O2-sulfonated diazeniumdiolatesRaechelle A D'Sa, Yuhong Wang, Patrick H Ruane, et al.
Inorganic Chemistry|March 17, 2011
HNO and NO release from a primary amine-based diazeniumdiolate as a function of pHDebra J Salmon, Claudia L Torres de Holding, Lynta Thomas, et al.
Leukemia Research|January 28, 2014
Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cellsMonika Z Kaczmarek, Ryan J Holland, Stephen A Lavanier, et al.
Journal of Medicinal Chemistry|October 19, 2011
Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugsAnna E Maciag, Rahul S Nandurdikar, Sam Y Hong, et al.
American Journal of Physiology. Heart and Circulatory Physiology|October 22, 2008
Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndromeSadaf S Ahanchi, Vinit N Varu, Nick D Tsihlis, et al.
NPJ Parkinson'S Disease|January 16, 2026
Microglial low-affinity FcγR mediates the phagocytic elimination of dopaminergic neurons in Parkinson's disease degenerationP V Casanova, I Freitag-Berenguel, E Saavedra-López, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 15, 2015
Hepatoselective Nitric Oxide (NO) Donors, V-PYRRO/NO and V-PROLI/NO, in Nonalcoholic Fatty Liver Disease: A Comparison of Antisteatotic Effects with the Biotransformation and PharmacokineticsKamil Kus, Maria Walczak, Edyta Maslak, et al.
Pageof 21

Showing results (181-190 of 209) with videos related to

Sort By:
Pageof 21
Journal of Medicinal Chemistry|July 11, 2006
Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivoPaul J Shami, Joseph E Saavedra, Challice L Bonifant, et al.
The Journal of Organic Chemistry|April 28, 2001
The secondary amine/nitric oxide complex ion R(2)N[N(O)NO](-) as nucleophile and leaving group in S9N)Ar reactionsJ E Saavedra, A Srinivasan, C L Bonifant, et al.
Anales De Pediatria (Barcelona, Spain : 2003)|February 6, 2004
[Change in attitude to bicycle helmets after serious accidents]M Fernández Sanmartín, P Cabanas Rodríguez, M Granero Asencio, et al.
The Journal of Organic Chemistry|January 18, 2003
Preparation and reactivity of O2-sulfonated diazeniumdiolatesRaechelle A D'Sa, Yuhong Wang, Patrick H Ruane, et al.
Inorganic Chemistry|March 17, 2011
HNO and NO release from a primary amine-based diazeniumdiolate as a function of pHDebra J Salmon, Claudia L Torres de Holding, Lynta Thomas, et al.
Leukemia Research|January 28, 2014
Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cellsMonika Z Kaczmarek, Ryan J Holland, Stephen A Lavanier, et al.
Journal of Medicinal Chemistry|October 19, 2011
Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugsAnna E Maciag, Rahul S Nandurdikar, Sam Y Hong, et al.
American Journal of Physiology. Heart and Circulatory Physiology|October 22, 2008
Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndromeSadaf S Ahanchi, Vinit N Varu, Nick D Tsihlis, et al.
NPJ Parkinson'S Disease|January 16, 2026
Microglial low-affinity FcγR mediates the phagocytic elimination of dopaminergic neurons in Parkinson's disease degenerationP V Casanova, I Freitag-Berenguel, E Saavedra-López, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 15, 2015
Hepatoselective Nitric Oxide (NO) Donors, V-PYRRO/NO and V-PROLI/NO, in Nonalcoholic Fatty Liver Disease: A Comparison of Antisteatotic Effects with the Biotransformation and PharmacokineticsKamil Kus, Maria Walczak, Edyta Maslak, et al.
Pageof 21